Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma
Key facts
- Who runs it
- Giselle Sholler
- Where
- Hershey, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 101 people, planned
- Starts
- 26 Nov 2026
- Expected to end
- 26 Nov 2040
- Type of study
- Interventional
- Treatments tested
- Naxitamab and GM-CSF in combination with irinotecan and temozolomide
- Dinutuximab. Immunotherapy
- DFMO
- Record updated
- 16 November 2026
Who can take part
- Age
- 1 year to 30 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Age; Participants must be age ≤ 21 years at High-Risk NB diagnosis; Participants must be >12 months of age at enrollment. Diagnosis; Participants must have a pathologically confirmed diagnosis of neuroblastoma and classified as high risk by the criteria used by COG or SIOPEN at the time of diagnosis; Exception: patients who are initially diagnosed as non high-risk neuroblastoma, but later converted to high-risk neuroblastoma are also eligible; Prior Therapy; Participants must have completed standard induction therapy for initial diagnosis of high-risk neuroblastoma (5-7 cycles of induction chemotherapy with or without anti-GD2 antibody as per section 4.2, may include an additional cycle of therapy given prior to starting HRNB induction), and local control (surgery). Participants will enroll after completion of upfront induction therapy; Disease Response; Participants must have a disease response by revised 2017 International Neuroblastoma Response Criteria (INRC) at the end of standard 5-7 cycles of Induction of GEIR:; o Overall INRC Response ≥PR or; o Primary tumor ≥SD, AND soft tissue/metastatic bone ≥PR, AND bone marrow ≥MD*; Includes bone marrow response of minimal disease or complete response. Timing; Start of therapy to occur ≤ 45 days after completion of last induction cycle (from last day of cycle); Organ Function Requirements; Hematological: Hematological recovery as defined by ANC ≥750/μL (unsupported- >24 hrs off G-CSF and 7 days off pegylated filgrastim); Renal: Participants must have adequate renal function defined:; o For participants < 17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Bedside Schwartz equation (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Bedside Schwartz equation is: [(0.413) X (Height in cm)] / SCr; o For participants ≥17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Cockcroft and Gault formula (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Cockcroft and Gault formula is: [(140-age) x (Wt in kg) x (0.85 if female)] / (72 x SCr); Cardiac: Adequate cardiac function defined as:; Shortening fraction of ≥28%, or; Ejection fraction of ≥50%; Liver: Adequate liver function defined as:; Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age; ALT (SGPT) < 10 x upper limit of normal (ULN) for age; Post-pubertal study participants must be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of <1% per year when used consistently and correctly) from the time of informed consent (and assent, as applicable) until 6 months after study treatment discontinuation. Participants who are lactating must agree to stop breast-feeding; Informed Consent: All participants and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines and applicable local regulations
Who cannot take part
- 1. Participants who are less than 1 year of age 2. Participants that had progressive disease (PD) at any time post cycle 4 during upfront induction therapy; Participants who required additional therapy after the end of standard Induction (5-7 cycles) to achieve adequate response; Investigational Drugs: Participants who are currently receiving another investigational drug are excluded from participation; Anti-cancer Agents: Participants who are currently receiving other anticancer agents are not eligible. Participants must have fully recovered from the hematological and bone marrow suppression effects of prior chemotherapy; Infection: Participants who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator; Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 1 and 30 years old?
This trial is currently available in United States.
- Penn State Milton S. Hershey Medical Center and Children's HospitalHershey, United StatesContact: Penn State Clinical TrialsTaking people
About the trial
What the trial wants to find out
A prospective, multicenter, clinical trial in participants with high-risk neuroblastoma that have completed induction therapy, evaluating the feasibility, efficacy, and toxicity of using anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF) as consolidation followed by standard radiation, then standard anti-GD2 immunotherapy, and 2 years of DFMO maintenance.
The group in the trial
- Consolidation with anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF)Treatment being tested
Consolidation Cycles 1-6: Naxitamab/Irinotecan/Temozolomide/GM-CSF + Radiation Immunotherapy Cycles 1-5: Dinutuximab + GM-CSF + Isotretinoin (or Dinutuximab-Beta) Immunotherapy Cycle 6: Isotretinoin alone DFMO Monotherapy: DFMO for 730 days (2 years)
Treatment: Naxitamab and GM-CSF in combination with irinotecan and temozolomide, Dinutuximab. Immunotherapy, and DFMO
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Beat Childhood Cancer Research Consortium Phase II Trial of Transplant-Free Chemo-immunotherapy Consolidation Regimen With Naxitamab for High-Risk Neuroblastoma
- Criteria questions
- Built from NCT07932808, who can take part
- Record updated
- 16 November 2026